Athersys Reports First Quarter 2023 Financial Results and Business Highlights

Author's Avatar
May 18, 2023

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update.